[Changes in laboratory and clinical parameters in subjects with chronic brucellosis treated with an immunomodulator: methisoprinol].
In order to evaluate the immunomodulating activity of isoprinosine in chronic infections, 7 patients with chronic brucellosis unresponsive to antibiotic and corticosteroid therapy were treated with 4 g/die of isoprinosine in association with antibiotic therapy from 3 to 6 months. Immunoserologic and clinical evaluation were obtained at regular intervals from each patient. The treatment induced a significant increase of E rosette formation, reduction of erythrocyte sedimentation rate, associated with improvement or disappearance of clinical symptoms. These data suggest that isoprinosine may favourably influence the clinical course of chronic brucellosis, probably modifying host cell-mediated immune response.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002006:Brucellosis / Q000188:drug therapy*; D002908:Chronic Disease; D004909:Erythrocyte Indices; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D012397:Rosette Formation
D000900:Anti-Bacterial Agents; D007288:Inosine; D007542:Inosine Pranobex
Modificazioni di alcuni parametri di laboratorio e clinici in soggetti con brucellosi cronica trattati con un immunomodulante: il metisoprinolo.